Kerry entered into a strategic licensing partnership with Pharma Foods International Co. Ltd. (PFI), where Kerry has access to the shared health technology developed by PFI.

Kerry (Dublin, Ireland) entered into a strategic licensing partnership with Pharma Foods International Co. Ltd. (PFI; Kyoto, Japan), where Kerry has access to the shared health technology developed by PFI. The ingredient promotes the natural production of hyaluronic acid, keeps the joints lubricated and flexible and ultimately helps reduce discomfort and stiffness in the knee joints and provide benefits for people with osteoarthritis.

“Our in-house consumer research has shown that consumers want healthy lifestyle products that are beneficial for bone and joint health,” said John Quilter, vice president and general manager of Kerry’s ProActive Health business, in a press release . “Today’s consumers are better informed about the ingredients in their functional products. 56% say they regularly look for ingredients that can help improve health. We’re excited to partner with PFI, a leader in functional ingredient innovation, for this new joint health technology, which complements our portfolio of branded, science-based ingredients including GanedenBC30 probiotic, Wellmune yeast beta-glucan and our latest addition Bio-K Plus Probiotics. “

Since the ingredient is soluble in water, it has no effect on the taste. It has already been formulated into several products in the Japanese market and Kerry will develop branding for the technology that supports application and development and supplies the ingredient to customers around the world.

“We are very excited to be working with Kerry,” said Dr. Mujo Kim, CEO of PFI, in a press release. “PFI has researched and developed original, unique materials for the global market. After we have established a collaborative relationship with Kerry, we can accelerate our global expansion. We anticipate strong synergies between PFI’s research capabilities and Kerry’s global trading network. “